HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kosei Hirakawa Selected Research

Ki23057

8/2011A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
2/2010Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.
11/2007A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver.
11/2006A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kosei Hirakawa Research Topics

Disease

234Neoplasms (Cancer)
03/2022 - 01/2002
124Stomach Neoplasms (Stomach Cancer)
11/2021 - 10/2003
100Breast Neoplasms (Breast Cancer)
03/2022 - 01/2002
85Neoplasm Metastasis (Metastasis)
02/2022 - 08/2002
55Colorectal Neoplasms (Colorectal Cancer)
03/2022 - 01/2003
46Carcinoma (Carcinomatosis)
11/2021 - 01/2003
33Pancreatic Neoplasms (Pancreatic Cancer)
01/2018 - 07/2003
30Lymphatic Metastasis
01/2021 - 05/2002
14Adenocarcinoma
12/2020 - 12/2003
14Rectal Neoplasms (Rectal Cancer)
09/2019 - 11/2010
13Colonic Neoplasms (Colon Cancer)
01/2019 - 08/2002
13Esophageal Neoplasms (Esophageal Cancer)
03/2017 - 05/2002
11Triple Negative Breast Neoplasms
03/2022 - 01/2011
11Hypoxia (Hypoxemia)
07/2021 - 01/2010
9Adenoma (Adenomas)
09/2017 - 11/2002
7Pathologic Constriction (Stenosis)
12/2019 - 03/2008
7Hemorrhage
11/2016 - 01/2006
7Microsatellite Instability
06/2010 - 01/2004
6Disease Progression
10/2021 - 11/2004
6Fibrosis (Cirrhosis)
01/2021 - 02/2007
6Carcinogenesis
04/2017 - 03/2006
6Crohn Disease (Crohn's Disease)
01/2015 - 03/2008
6Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2014 - 11/2009
5Lung Neoplasms (Lung Cancer)
12/2020 - 08/2004
5Anaplastic Thyroid Carcinoma
12/2016 - 12/2002
5Ulcerative Colitis
11/2015 - 08/2008
4Vascular Remodeling
02/2022 - 01/2018
4Anastomotic Leak
12/2021 - 05/2014
4Infections
05/2019 - 07/2006

Drug/Important Bio-Agent (IBA)

32Fluorouracil (Carac)FDA LinkGeneric
10/2021 - 10/2003
31Proteins (Proteins, Gene)FDA Link
01/2019 - 07/2003
26Biomarkers (Surrogate Marker)IBA
01/2022 - 10/2005
22Messenger RNA (mRNA)IBA
01/2018 - 12/2003
20Paclitaxel (Taxol)FDA LinkGeneric
12/2020 - 05/2002
18Hormones (Hormone)IBA
03/2022 - 01/2009
18eribulinFDA Link
02/2022 - 11/2013
18Phenobarbital (Luminal)FDA Link
01/2022 - 11/2012
17Indicators and Reagents (Reagents)IBA
10/2021 - 10/2005
14ErbB Receptors (EGF Receptor)IBA
03/2022 - 02/2005
14Trastuzumab (Herceptin)FDA Link
12/2020 - 10/2003
13C-Reactive ProteinIBA
05/2021 - 11/2013
12Biological ProductsIBA
01/2020 - 12/2003
12Cisplatin (Platino)FDA LinkGeneric
12/2019 - 02/2004
12GemcitabineFDA Link
01/2017 - 06/2005
12Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2016 - 08/2004
11Pharmaceutical PreparationsIBA
01/2022 - 11/2004
11Docetaxel (Taxotere)FDA Link
12/2020 - 07/2005
11Estrogen ReceptorsIBA
08/2020 - 05/2002
11Transforming Growth Factor beta (TGF-beta)IBA
01/2017 - 02/2007
10Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2020 - 07/2003
10AntigensIBA
06/2020 - 12/2009
10Small Interfering RNA (siRNA)IBA
04/2016 - 10/2005
10Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
11/2014 - 08/2002
9Bevacizumab (Avastin)FDA Link
07/2021 - 08/2012
9Epirubicin (Ellence)FDA LinkGeneric
12/2020 - 10/2003
9Oxaliplatin (Eloxatin)FDA LinkGeneric
12/2019 - 09/2006
8human ERBB2 proteinIBA
02/2022 - 01/2011
8Therapeutic UsesIBA
10/2021 - 01/2016
8DNA (Deoxyribonucleic Acid)IBA
01/2018 - 11/2002
8ParaffinIBA
07/2017 - 11/2002
8Cadherins (E-Cadherin)IBA
07/2017 - 01/2011
8Vascular Endothelial Growth Factor CIBA
08/2016 - 01/2003
7taxaneIBA
02/2022 - 05/2005
7AntibodiesIBA
01/2021 - 04/2009
7VimentinIBA
03/2017 - 10/2004
7Progesterone Receptors (Progesterone Receptor)IBA
04/2016 - 01/2004
7Phosphotransferases (Kinase)IBA
08/2012 - 06/2004
6pertuzumabIBA
12/2020 - 01/2015
6Hematoxylin (Haematoxylon)IBA
12/2018 - 05/2007
6Eosine Yellowish-(YS) (Eosin)IBA
12/2018 - 05/2007
6TegafurIBA
09/2018 - 06/2004
6CytokinesIBA
02/2018 - 09/2004
6LigandsIBA
01/2018 - 12/2002
6Transforming Growth Factors (Transforming Growth Factor)IBA
01/2018 - 02/2007
6EnzymesIBA
12/2017 - 11/2006
5AlbuminsIBA
02/2019 - 05/2015
5Formaldehyde (Formol)FDA Link
07/2017 - 11/2002
5MicroRNAs (MicroRNA)IBA
10/2016 - 02/2014
5Conditioned Culture MediaIBA
11/2014 - 04/2005
5Irinotecan (Camptosar)FDA LinkGeneric
11/2014 - 09/2006
4Dacarbazine (DIC)FDA LinkGeneric
12/2020 - 11/2014
4MucinsIBA
05/2019 - 01/2004

Therapy/Procedure

89Drug Therapy (Chemotherapy)
11/2021 - 10/2003
81Therapeutics
01/2022 - 05/2002
32Neoadjuvant Therapy
03/2022 - 10/2009
27Gastrectomy
11/2021 - 07/2005
14Radiotherapy
01/2021 - 08/2004
13Adjuvant Chemotherapy
11/2021 - 03/2004
11Lymph Node Excision (Lymph Node Dissection)
01/2021 - 11/2012
10Combination Drug Therapy (Combination Chemotherapy)
03/2019 - 07/2003
9Aftercare (After-Treatment)
01/2022 - 06/2004
9Chemoradiotherapy
11/2017 - 11/2009
8Esophagectomy
03/2017 - 02/2013
7Segmental Mastectomy (Lumpectomy)
12/2020 - 11/2011
7Length of Stay
05/2014 - 06/2010
5Immunotherapy
04/2021 - 01/2006
5Adrenalectomy
09/2017 - 01/2006
5Pancreatectomy
01/2017 - 01/2013
4Thyroidectomy
01/2021 - 01/2012
4Mastectomy (Mammectomy)
01/2020 - 11/2011